| Ticker | MLYS |
|---|---|
| ISIN | US6031701013 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
El precio actual de Mineralys Therapeutics, Inc. (MLYS) es de 27,51 , con una variación del -3,44%.
Mineralys Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.